Difference between revisions of "Joint Supplements"
User:Fellrnr (User talk:Fellrnr | contribs) (Created page with "Knee pain is one of the most common running problems. The joint supplements glucosamine and chondroitin provide marginal bene...") |
User:Fellrnr (User talk:Fellrnr | contribs) |
||
(3 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
− | [[File:KneePainFigure m flip.jpg|right|thumb|400px|Knee | + | [[File:KneePainFigure m flip.jpg|right|thumb|400px|[[Knee Pain]] is one of the most common running problems.]] |
The joint supplements glucosamine and chondroitin provide marginal benefit, but are considered safe. They may be worth considering if you can justify the expense. Other supplements such as [[Omega 3]] oils and Vitamin C/E may be worth considering. | The joint supplements glucosamine and chondroitin provide marginal benefit, but are considered safe. They may be worth considering if you can justify the expense. Other supplements such as [[Omega 3]] oils and Vitamin C/E may be worth considering. | ||
=Glucosamine and chondroitin= | =Glucosamine and chondroitin= | ||
− | Chondroitin is an important component of joint cartilage and glucosamine is building block for other joint structures. Both chondroitin and glucosamine taken orally reach the joint space<ref name="JointChAbs"/><ref name="JointChAbs2"/><ref name="JointGluAbs"/>. There have been over 500 studies of glucosamine and chondroitin<ref name="JointAIM"/>, and analysis of the best of the studies show only a marginal benefit<ref name="JointBMJ"/><ref name="JointAnnIM"/><ref name="JointArthRheum"/> or provide benefit only to a subgroup of suffers<ref name="JointNEJM"/>. These benefits do not meet the requirements to be generally considered clinically important<ref name="JointBMJ"/>. However, given the safety of these supplements, they may be worth considering if your income is sufficient. | + | Chondroitin is an important component of joint cartilage and glucosamine is building block for other joint structures. Both chondroitin and glucosamine taken orally reach the joint space<ref name="JointChAbs"/><ref name="JointChAbs2"/><ref name="JointGluAbs"/>. There have been over 500 studies of glucosamine and chondroitin<ref name="JointAIM"/>, and analysis of the best of the studies show only a marginal benefit<ref name="JointBMJ"/><ref name="JointAnnIM"/><ref name="JointArthRheum"/> or provide benefit only to a subgroup of suffers<ref name="JointNEJM"/>. These benefits do not meet the requirements to be generally considered clinically important<ref name="JointBMJ"/>. One review noted that the benefit of these suppliments is confused by a high rate of response to placebos<ref name="DiNubile2018"/>, suggesting that the belief in their efficacy is important. However, given the safety of these supplements, they may be worth considering if your income is sufficient. |
==Dosage== | ==Dosage== | ||
Doses of less than 800 mg/day of chondroitin or less than 1500 mg/day of glucosamine are considered sub-therapeutic<ref name="JointBMJ"/>, but there is no indication of appropriate dose. The Mayo Clinic suggest 500mg Glucosamine sulfate three times a day or 20mg per Kg body weight<ref name="GlucosDose"/> and 200-400mg chondroitin 2-3 times daily<ref name="ChondDose"/>. These doses are based on those commonly used in studies. | Doses of less than 800 mg/day of chondroitin or less than 1500 mg/day of glucosamine are considered sub-therapeutic<ref name="JointBMJ"/>, but there is no indication of appropriate dose. The Mayo Clinic suggest 500mg Glucosamine sulfate three times a day or 20mg per Kg body weight<ref name="GlucosDose"/> and 200-400mg chondroitin 2-3 times daily<ref name="ChondDose"/>. These doses are based on those commonly used in studies. | ||
=Cost= | =Cost= | ||
I found glucosamine and chondroitin available online for about $10/month. Look carefully at the ingredients to check how many capsules make up the stated dose when calculating the daily cost. | I found glucosamine and chondroitin available online for about $10/month. Look carefully at the ingredients to check how many capsules make up the stated dose when calculating the daily cost. | ||
+ | =Cancer Risk= | ||
+ | One study found a small reduction in the rates of colorectal cancer from glucosamine and chondroitin based on the review of two large groups of healthcare professionals<ref name="KantorZhang2016"/>. Another study of found reduced rates colorectal cancer from glucosamine<ref name="KantorNewton2018"/>. One theory is that glucosamine and chondroitin act as an anti-inflammatory. | ||
=Food for joints= | =Food for joints= | ||
There have been over 2,000 studies of related to nutrition and Osteoarthritis, but only 53 are of sufficient quality to be useful<ref name="JointNutra"/>. Some options that may be worth considering include: | There have been over 2,000 studies of related to nutrition and Osteoarthritis, but only 53 are of sufficient quality to be useful<ref name="JointNutra"/>. Some options that may be worth considering include: | ||
Line 13: | Line 15: | ||
* There is some suggestion that [[Omega 3]] oils may help with Osteoarthritis<ref name="JointO3GPig"/><ref name="JointO3Most"/>. Given the other health benefits of [[Omega 3]] oils, supplementation should be considered. | * There is some suggestion that [[Omega 3]] oils may help with Osteoarthritis<ref name="JointO3GPig"/><ref name="JointO3Most"/>. Given the other health benefits of [[Omega 3]] oils, supplementation should be considered. | ||
* Higher Vitamin C intake may reduce Osteoarthritis<ref name="JointVitCFraming"/> and 1000mg/day of Vitamin C reduced joint pain, though by less than half what would be expected from [[NSAIDs and Running|NSAIDs]]<ref name="JointVitC1g"/>. Like [[Omega 3]] there may be other benefits to Vitamin C supplementation that make this worthwhile. | * Higher Vitamin C intake may reduce Osteoarthritis<ref name="JointVitCFraming"/> and 1000mg/day of Vitamin C reduced joint pain, though by less than half what would be expected from [[NSAIDs and Running|NSAIDs]]<ref name="JointVitC1g"/>. Like [[Omega 3]] there may be other benefits to Vitamin C supplementation that make this worthwhile. | ||
− | * Some<ref name="JointVitEP1"/><ref name="JointVitEP2"/><ref name=" | + | * Some<ref name="JointVitEP1"/><ref name="JointVitEP2"/><ref name="Scherak-1990"/>, but not all<ref name="Brand-2001"/><ref name="JointVitEN2"/> studies have shown benefit from Vitamin E supplementation. Like the above two supplements, Vitamin E should be considered as there may be other health benefits. |
− | * Devil's Claw, a South African plan extract, may help with joint pain (60mg harpagoside)<ref name=" | + | * Devil's Claw, a South African plan extract, may help with joint pain (60mg harpagoside)<ref name=" Gagnier-2004"/>. However, there is little known about its safety. |
− | |||
− | |||
=References= | =References= | ||
<references> | <references> | ||
<ref name="ChondDose">Chondroitin sulfate: Dosing - MayoClinic.com http://www.mayoclinic.com/health/chondroitin-sulfate/NS_patient-chondroitin/DSECTION=dosing </ref> | <ref name="ChondDose">Chondroitin sulfate: Dosing - MayoClinic.com http://www.mayoclinic.com/health/chondroitin-sulfate/NS_patient-chondroitin/DSECTION=dosing </ref> | ||
<ref name="GlucosDose">Glucosamine: Dosing - MayoClinic.com http://www.mayoclinic.com/health/glucosamine/ns_patient-glucosamine/dsection=dosing </ref> | <ref name="GlucosDose">Glucosamine: Dosing - MayoClinic.com http://www.mayoclinic.com/health/glucosamine/ns_patient-glucosamine/dsection=dosing </ref> | ||
− | <ref name=" | + | <ref name="Gagnier-2004">JJ. Gagnier, S. Chrubasik, E. Manheimer, Harpgophytum procumbens for osteoarthritis and low back pain: a systematic review., BMC Complement Altern Med, volume 4, pages 13, Sep 2004, doi [http://dx.doi.org/10.1186/1472-6882-4-13 10.1186/1472-6882-4-13], PMID [http://www.ncbi.nlm.nih.gov/pubmed/15369596 15369596]</ref> |
− | <ref name="JointVitEN2">Supplementary vitamin E does not affect the loss. | + | <ref name="JointVitEN2">AE. Wluka, S. Stuckey, C. Brand, FM. Cicuttini, Supplementary vitamin E does not affect the loss of cartilage volume in knee osteoarthritis: a 2 year double blind randomized placebo controlled study., J Rheumatol, volume 29, issue 12, pages 2585-91, Dec 2002, PMID [http://www.ncbi.nlm.nih.gov/pubmed/12465157 12465157]</ref> |
− | <ref name=" | + | <ref name="Brand-2001">C. Brand, J. Snaddon, M. Bailey, F. Cicuttini, Vitamin E is ineffective for symptomatic relief of knee osteoarthritis: a six month double blind, randomised, placebo controlled study., Ann Rheum Dis, volume 60, issue 10, pages 946-9, Oct 2001, PMID [http://www.ncbi.nlm.nih.gov/pubmed/11557651 11557651]</ref> |
− | <ref name=" | + | <ref name="Scherak-1990">O. Scherak, G. Kolarz, C. Schödl, G. Blankenhorn, High dosage vitamin E therapy in patients with activated arthrosis., Z Rheumatol, volume 49, issue 6, pages 369-73, PMID [http://www.ncbi.nlm.nih.gov/pubmed/2085059 2085059]</ref> |
− | <ref name="JointVitEP2"> | + | <ref name="JointVitEP2">G. Blankenhorn, Clinical effectiveness of Spondyvit (vitamin E) in activated arthroses. A multicenter placebo-controlled double-blind study., Z Orthop Ihre Grenzgeb, volume 124, issue 3, pages 340-3, doi [http://dx.doi.org/10.1055/s-2008-1044572 10.1055/s-2008-1044572], PMID [http://www.ncbi.nlm.nih.gov/pubmed/3529677 3529677]</ref> |
− | <ref name="JointVitEP1"> | + | <ref name="JointVitEP1">I. Machtey, L. Ouaknine, Tocopherol in Osteoarthritis: a controlled pilot study., J Am Geriatr Soc, volume 26, issue 7, pages 328-30, Jul 1978, PMID [http://www.ncbi.nlm.nih.gov/pubmed/350940 350940]</ref> |
− | <ref name="JointVitC1g">[Reduced pain from osteoarthritis in hip joint.. | + | <ref name="JointVitC1g">NH. Jensen, [Reduced pain from osteoarthritis in hip joint or knee joint during treatment with calcium ascorbate. A randomized, placebo-controlled cross-over trial in general practice]., Ugeskr Laeger, volume 165, issue 25, pages 2563-6, Jun 2003, PMID [http://www.ncbi.nlm.nih.gov/pubmed/12854267 12854267]</ref> |
− | <ref name="JointVitCFraming"> | + | <ref name="JointVitCFraming">TE. McAlindon, P. Jacques, Y. Zhang, MT. Hannan, P. Aliabadi, B. Weissman, D. Rush, D. Levy, DT. Felson, Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis?, Arthritis Rheum, volume 39, issue 4, pages 648-56, Apr 1996, PMID [http://www.ncbi.nlm.nih.gov/pubmed/8630116 8630116]</ref> |
− | + | <ref name="JointO3Most"> K.R. Baker, N.R. Matthan, A.H. Lichtenstein, J. Niu, A. Guermazi, F. Roemer, A. Grainger, M.C. Nevitt, M. Clancy, C.E. Lewis, J.C. Torner, D.T. Felson, Association of plasma n-6 and n-3 polyunsaturated fatty acids with synovitis in the knee: the MOST study, Osteoarthritis and Cartilage, volume 20, issue 5, 2012, pages 382–387, ISSN [http://www.worldcat.org/issn/10634584 10634584], doi [http://dx.doi.org/10.1016/j.joca.2012.01.021 10.1016/j.joca.2012.01.021]</ref> | |
− | <ref name=" | + | <ref name="JointO3GPig"> L. Knott, N.C. Avery, A.P. Hollander, J.F. Tarlton, Regulation of osteoarthritis by omega-3 (n-3) polyunsaturated fatty acids in a naturally occurring model of disease, Osteoarthritis and Cartilage, volume 19, issue 9, 2011, pages 1150–1157, ISSN [http://www.worldcat.org/issn/10634584 10634584], doi [http://dx.doi.org/10.1016/j.joca.2011.06.005 10.1016/j.joca.2011.06.005]</ref> |
− | + | <ref name="JointASU4">E. Maheu, B. Mazières, JP. Valat, G. Loyau, X. Le Loët, P. Bourgeois, JM. Grouin, S. Rozenberg, Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect., Arthritis Rheum, volume 41, issue 1, pages 81-91, Jan 1998, doi [http://dx.doi.org/10.1002/1529-0131(199801)41:1<81::AID-ART11>3.0.CO;2-9 10.1002/1529-0131(199801)41:1<81::AID-ART11>3.0.CO;2-9], PMID [http://www.ncbi.nlm.nih.gov/pubmed/9433873 9433873]</ref> | |
− | <ref name=" | + | <ref name="JointASU3">T. Appelboom, J. Schuermans, G. Verbruggen, Y. Henrotin, JY. Reginster, Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study., Scand J Rheumatol, volume 30, issue 4, pages 242-7, 2001, PMID [http://www.ncbi.nlm.nih.gov/pubmed/11578021 11578021]</ref> |
− | + | <ref name="JointASU2">F. Blotman, E. Maheu, A. Wulwik, H. Caspard, A. Lopez, Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial., Rev Rhum Engl Ed, volume 64, issue 12, pages 825-34, Dec 1997, PMID [http://www.ncbi.nlm.nih.gov/pubmed/9476272 9476272]</ref> | |
− | <ref name=" | + | <ref name="JointASU1">M. Lequesne, E. Maheu, C. Cadet, RL. Dreiser, Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip., Arthritis Rheum, volume 47, issue 1, pages 50-8, Feb 2002, PMID [http://www.ncbi.nlm.nih.gov/pubmed/11932878 11932878]</ref> |
− | + | <ref name="JointNutra"> Laurent G Ameye, Winnie SS Chee, Arthritis Research & Therapy, volume 8, issue 4, 2006, pages R127, ISSN [http://www.worldcat.org/issn/14786354 14786354], doi [http://dx.doi.org/10.1186/ar2016 10.1186/ar2016]</ref> | |
− | + | <ref name="JointGluAbs">S. Persiani, R. Rotini, G. Trisolino, LC. Rovati, M. Locatelli, D. Paganini, D. Antonioli, A. Roda, Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose., Osteoarthritis Cartilage, volume 15, issue 7, pages 764-72, Jul 2007, doi [http://dx.doi.org/10.1016/j.joca.2007.01.019 10.1016/j.joca.2007.01.019], PMID [http://www.ncbi.nlm.nih.gov/pubmed/17353133 17353133]</ref> | |
− | + | <ref name="JointChAbs2">F. Ronca, L. Palmieri, P. Panicucci, G. Ronca, Anti-inflammatory activity of chondroitin sulfate., Osteoarthritis Cartilage, volume 6 Suppl A, pages 14-21, May 1998, PMID [http://www.ncbi.nlm.nih.gov/pubmed/9743814 9743814]</ref> | |
− | <ref name=" | + | <ref name="JointChAbs">A. Conte, N. Volpi, L. Palmieri, I. Bahous, G. Ronca, Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate., Arzneimittelforschung, volume 45, issue 8, pages 918-25, Aug 1995, PMID [http://www.ncbi.nlm.nih.gov/pubmed/7575762 7575762]</ref> |
− | <ref name=" | + | <ref name="JointMSMBrain2">A. Lin, CH. Nguy, F. Shic, BD. Ross, Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy., Toxicol Lett, volume 123, issue 2-3, pages 169-77, Sep 2001, PMID [http://www.ncbi.nlm.nih.gov/pubmed/11641045 11641045]</ref> |
− | <ref name=" | + | <ref name="JointMSMBrain1">SE. Rose, JB. Chalk, GJ. Galloway, DM. Doddrell, Detection of dimethyl sulfone in the human brain by in vivo proton magnetic resonance spectroscopy., Magn Reson Imaging, volume 18, issue 1, pages 95-8, Jan 2000, PMID [http://www.ncbi.nlm.nih.gov/pubmed/10642107 10642107]</ref> |
− | <ref name=" | + | <ref name="JointMSM3">PR. Usha, MU. Naidu, Randomised, Double-Blind, Parallel, Placebo-Controlled Study of Oral Glucosamine, Methylsulfonylmethane and their Combination in Osteoarthritis., Clin Drug Investig, volume 24, issue 6, pages 353-63, 2004, PMID [http://www.ncbi.nlm.nih.gov/pubmed/17516722 17516722]</ref> |
− | <ref name=" | + | <ref name="JointMSM2">LS. Kim, LJ. Axelrod, P. Howard, N. Buratovich, RF. Waters, Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial., Osteoarthritis Cartilage, volume 14, issue 3, pages 286-94, Mar 2006, doi [http://dx.doi.org/10.1016/j.joca.2005.10.003 10.1016/j.joca.2005.10.003], PMID [http://www.ncbi.nlm.nih.gov/pubmed/16309928 16309928]</ref> |
− | + | <ref name="JointMSM">S. Brien, P. Prescott, N. Bashir, H. Lewith, G. Lewith, Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis., Osteoarthritis Cartilage, volume 16, issue 11, pages 1277-88, Nov 2008, doi [http://dx.doi.org/10.1016/j.joca.2008.03.002 10.1016/j.joca.2008.03.002], PMID [http://www.ncbi.nlm.nih.gov/pubmed/18417375 18417375]</ref> | |
− | <ref name=" | + | <ref name="JointNEJM">DO. Clegg, DJ. Reda, CL. Harris, MA. Klein, JR. O'Dell, MM. Hooper, JD. Bradley, CO. Bingham, MH. Weisman, Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis., N Engl J Med, volume 354, issue 8, pages 795-808, Feb 2006, doi [http://dx.doi.org/10.1056/NEJMoa052771 10.1056/NEJMoa052771], PMID [http://www.ncbi.nlm.nih.gov/pubmed/16495392 16495392]</ref> |
− | <ref name=" | + | <ref name="JointAIM"> Florent Richy, Olivier Bruyere, Olivier Ethgen, Michel Cucherat, Yves Henrotin, Jean-Yves Reginster, Structural and Symptomatic Efficacy of Glucosamine and Chondroitin in Knee Osteoarthritis, Archives of Internal Medicine, volume 163, issue 13, 2003, pages 1514, ISSN [http://www.worldcat.org/issn/0003-9926 0003-9926], doi [http://dx.doi.org/10.1001/archinte.163.13.1514 10.1001/archinte.163.13.1514]</ref> |
− | <ref name=" | + | <ref name="JointBMJ"> S. Wandel, P. Juni, B. Tendal, E. Nuesch, P. M. Villiger, N. J. Welton, S. Reichenbach, S. Trelle, Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis, BMJ, volume 341, issue sep16 2, 2010, pages c4675–c4675, ISSN [http://www.worldcat.org/issn/0959-8138 0959-8138], doi [http://dx.doi.org/10.1136/bmj.c4675 10.1136/bmj.c4675]</ref> |
− | <ref name=" | + | <ref name="JointAnnIM">S. Reichenbach, R. Sterchi, M. Scherer, S. Trelle, E. Bürgi, U. Bürgi, PA. Dieppe, P. Jüni, Meta-analysis: chondroitin for osteoarthritis of the knee or hip., Ann Intern Med, volume 146, issue 8, pages 580-90, Apr 2007, PMID [http://www.ncbi.nlm.nih.gov/pubmed/17438317 17438317]</ref> |
− | <ref name=" | + | <ref name="JointArthRheum">SC. Vlad, MP. LaValley, TE. McAlindon, DT. Felson, Glucosamine for pain in osteoarthritis: why do trial results differ?, Arthritis Rheum, volume 56, issue 7, pages 2267-77, Jul 2007, doi [http://dx.doi.org/10.1002/art.22728 10.1002/art.22728], PMID [http://www.ncbi.nlm.nih.gov/pubmed/17599746 17599746]</ref> |
+ | <ref name="KantorZhang2016">Elizabeth D. Kantor, Xuehong Zhang, Kana Wu, Lisa B. Signorello, Andrew T. Chan, Charles S. Fuchs, Edward L. Giovannucci, Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study, International Journal of Cancer, volume 139, issue 9, 2016, pages 1949–1957, ISSN [http://www.worldcat.org/issn/00207136 00207136], doi [http://dx.doi.org/10.1002/ijc.30250 10.1002/ijc.30250]</ref> | ||
+ | <ref name="KantorNewton2018">Elizabeth D. Kantor, Christina C. Newton, Edward L. Giovannucci, Marjorie L. McCullough, Peter T. Campbell, Eric J. Jacobs, Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort, Cancer Causes & Control, volume 29, issue 3, 2018, pages 389–397, ISSN [http://www.worldcat.org/issn/0957-5243 0957-5243], doi [http://dx.doi.org/10.1007/s10552-018-1003-6 10.1007/s10552-018-1003-6]</ref> | ||
+ | <ref name="DiNubile2018">Nicholas DiNubile, Glucosamine and Chondroitin Sulfate: What Has Been Learned Since the Glucosamine/chondroitin Arthritis Intervention Trial, Orthopedics, volume 41, issue 4, 2018, pages 200–207, ISSN [http://www.worldcat.org/issn/0147-7447 0147-7447], doi [http://dx.doi.org/10.3928/01477447-20180511-06 10.3928/01477447-20180511-06]</ref> | ||
+ | <ref name="DiNubile2018">Nicholas DiNubile, Glucosamine and Chondroitin Sulfate: What Has Been Learned Since the Glucosamine/chondroitin Arthritis Intervention Trial, Orthopedics, volume 41, issue 4, 2018, pages 200–207, ISSN [http://www.worldcat.org/issn/0147-7447 0147-7447], doi [http://dx.doi.org/10.3928/01477447-20180511-06 10.3928/01477447-20180511-06]</ref> | ||
</references> | </references> |
Latest revision as of 13:45, 6 May 2019
The joint supplements glucosamine and chondroitin provide marginal benefit, but are considered safe. They may be worth considering if you can justify the expense. Other supplements such as Omega 3 oils and Vitamin C/E may be worth considering.
Contents
1 Glucosamine and chondroitin
Chondroitin is an important component of joint cartilage and glucosamine is building block for other joint structures. Both chondroitin and glucosamine taken orally reach the joint space[1][2][3]. There have been over 500 studies of glucosamine and chondroitin[4], and analysis of the best of the studies show only a marginal benefit[5][6][7] or provide benefit only to a subgroup of suffers[8]. These benefits do not meet the requirements to be generally considered clinically important[5]. One review noted that the benefit of these suppliments is confused by a high rate of response to placebos[9], suggesting that the belief in their efficacy is important. However, given the safety of these supplements, they may be worth considering if your income is sufficient.
1.1 Dosage
Doses of less than 800 mg/day of chondroitin or less than 1500 mg/day of glucosamine are considered sub-therapeutic[5], but there is no indication of appropriate dose. The Mayo Clinic suggest 500mg Glucosamine sulfate three times a day or 20mg per Kg body weight[10] and 200-400mg chondroitin 2-3 times daily[11]. These doses are based on those commonly used in studies.
2 Cost
I found glucosamine and chondroitin available online for about $10/month. Look carefully at the ingredients to check how many capsules make up the stated dose when calculating the daily cost.
3 Cancer Risk
One study found a small reduction in the rates of colorectal cancer from glucosamine and chondroitin based on the review of two large groups of healthcare professionals[12]. Another study of found reduced rates colorectal cancer from glucosamine[13]. One theory is that glucosamine and chondroitin act as an anti-inflammatory.
4 Food for joints
There have been over 2,000 studies of related to nutrition and Osteoarthritis, but only 53 are of sufficient quality to be useful[14]. Some options that may be worth considering include:
- Methylsulfonylmethane (MSM) is a less well known joint supplement than glucosamine and chondroitin, with far less studies available. There is some support for MSM helping with joint pain[15][16], but not enough to give confidence as to its effectiveness or safety[17]. MSM does cross the blood/brain barrier[18][19] and may cause headaches[15]. (I believe MSM was a trigger for my migraines.)
- The supplement "avocado/soybean unsaponifiables" has shown positive results in studies[20][21][22][23]. However, this supplement has not been widely studies for effectiveness or long term safety.
- There is some suggestion that Omega 3 oils may help with Osteoarthritis[24][25]. Given the other health benefits of Omega 3 oils, supplementation should be considered.
- Higher Vitamin C intake may reduce Osteoarthritis[26] and 1000mg/day of Vitamin C reduced joint pain, though by less than half what would be expected from NSAIDs[27]. Like Omega 3 there may be other benefits to Vitamin C supplementation that make this worthwhile.
- Some[28][29][30], but not all[31][32] studies have shown benefit from Vitamin E supplementation. Like the above two supplements, Vitamin E should be considered as there may be other health benefits.
- Devil's Claw, a South African plan extract, may help with joint pain (60mg harpagoside)[33]. However, there is little known about its safety.
5 References
- ↑ A. Conte, N. Volpi, L. Palmieri, I. Bahous, G. Ronca, Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate., Arzneimittelforschung, volume 45, issue 8, pages 918-25, Aug 1995, PMID 7575762
- ↑ F. Ronca, L. Palmieri, P. Panicucci, G. Ronca, Anti-inflammatory activity of chondroitin sulfate., Osteoarthritis Cartilage, volume 6 Suppl A, pages 14-21, May 1998, PMID 9743814
- ↑ S. Persiani, R. Rotini, G. Trisolino, LC. Rovati, M. Locatelli, D. Paganini, D. Antonioli, A. Roda, Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose., Osteoarthritis Cartilage, volume 15, issue 7, pages 764-72, Jul 2007, doi 10.1016/j.joca.2007.01.019, PMID 17353133
- ↑ Florent Richy, Olivier Bruyere, Olivier Ethgen, Michel Cucherat, Yves Henrotin, Jean-Yves Reginster, Structural and Symptomatic Efficacy of Glucosamine and Chondroitin in Knee Osteoarthritis, Archives of Internal Medicine, volume 163, issue 13, 2003, pages 1514, ISSN 0003-9926, doi 10.1001/archinte.163.13.1514
- ↑ 5.0 5.1 5.2 S. Wandel, P. Juni, B. Tendal, E. Nuesch, P. M. Villiger, N. J. Welton, S. Reichenbach, S. Trelle, Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis, BMJ, volume 341, issue sep16 2, 2010, pages c4675–c4675, ISSN 0959-8138, doi 10.1136/bmj.c4675
- ↑ S. Reichenbach, R. Sterchi, M. Scherer, S. Trelle, E. Bürgi, U. Bürgi, PA. Dieppe, P. Jüni, Meta-analysis: chondroitin for osteoarthritis of the knee or hip., Ann Intern Med, volume 146, issue 8, pages 580-90, Apr 2007, PMID 17438317
- ↑ SC. Vlad, MP. LaValley, TE. McAlindon, DT. Felson, Glucosamine for pain in osteoarthritis: why do trial results differ?, Arthritis Rheum, volume 56, issue 7, pages 2267-77, Jul 2007, doi 10.1002/art.22728, PMID 17599746
- ↑ DO. Clegg, DJ. Reda, CL. Harris, MA. Klein, JR. O'Dell, MM. Hooper, JD. Bradley, CO. Bingham, MH. Weisman, Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis., N Engl J Med, volume 354, issue 8, pages 795-808, Feb 2006, doi 10.1056/NEJMoa052771, PMID 16495392
- ↑ Nicholas DiNubile, Glucosamine and Chondroitin Sulfate: What Has Been Learned Since the Glucosamine/chondroitin Arthritis Intervention Trial, Orthopedics, volume 41, issue 4, 2018, pages 200–207, ISSN 0147-7447, doi 10.3928/01477447-20180511-06
- ↑ Glucosamine: Dosing - MayoClinic.com http://www.mayoclinic.com/health/glucosamine/ns_patient-glucosamine/dsection=dosing
- ↑ Chondroitin sulfate: Dosing - MayoClinic.com http://www.mayoclinic.com/health/chondroitin-sulfate/NS_patient-chondroitin/DSECTION=dosing
- ↑ Elizabeth D. Kantor, Xuehong Zhang, Kana Wu, Lisa B. Signorello, Andrew T. Chan, Charles S. Fuchs, Edward L. Giovannucci, Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study, International Journal of Cancer, volume 139, issue 9, 2016, pages 1949–1957, ISSN 00207136, doi 10.1002/ijc.30250
- ↑ Elizabeth D. Kantor, Christina C. Newton, Edward L. Giovannucci, Marjorie L. McCullough, Peter T. Campbell, Eric J. Jacobs, Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort, Cancer Causes & Control, volume 29, issue 3, 2018, pages 389–397, ISSN 0957-5243, doi 10.1007/s10552-018-1003-6
- ↑ Laurent G Ameye, Winnie SS Chee, Arthritis Research & Therapy, volume 8, issue 4, 2006, pages R127, ISSN 14786354, doi 10.1186/ar2016
- ↑ 15.0 15.1 LS. Kim, LJ. Axelrod, P. Howard, N. Buratovich, RF. Waters, Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial., Osteoarthritis Cartilage, volume 14, issue 3, pages 286-94, Mar 2006, doi 10.1016/j.joca.2005.10.003, PMID 16309928
- ↑ PR. Usha, MU. Naidu, Randomised, Double-Blind, Parallel, Placebo-Controlled Study of Oral Glucosamine, Methylsulfonylmethane and their Combination in Osteoarthritis., Clin Drug Investig, volume 24, issue 6, pages 353-63, 2004, PMID 17516722
- ↑ S. Brien, P. Prescott, N. Bashir, H. Lewith, G. Lewith, Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis., Osteoarthritis Cartilage, volume 16, issue 11, pages 1277-88, Nov 2008, doi 10.1016/j.joca.2008.03.002, PMID 18417375
- ↑ SE. Rose, JB. Chalk, GJ. Galloway, DM. Doddrell, Detection of dimethyl sulfone in the human brain by in vivo proton magnetic resonance spectroscopy., Magn Reson Imaging, volume 18, issue 1, pages 95-8, Jan 2000, PMID 10642107
- ↑ A. Lin, CH. Nguy, F. Shic, BD. Ross, Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy., Toxicol Lett, volume 123, issue 2-3, pages 169-77, Sep 2001, PMID 11641045
- ↑ M. Lequesne, E. Maheu, C. Cadet, RL. Dreiser, Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip., Arthritis Rheum, volume 47, issue 1, pages 50-8, Feb 2002, PMID 11932878
- ↑ F. Blotman, E. Maheu, A. Wulwik, H. Caspard, A. Lopez, Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial., Rev Rhum Engl Ed, volume 64, issue 12, pages 825-34, Dec 1997, PMID 9476272
- ↑ T. Appelboom, J. Schuermans, G. Verbruggen, Y. Henrotin, JY. Reginster, Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study., Scand J Rheumatol, volume 30, issue 4, pages 242-7, 2001, PMID 11578021
- ↑ E. Maheu, B. Mazières, JP. Valat, G. Loyau, X. Le Loët, P. Bourgeois, JM. Grouin, S. Rozenberg, Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect., Arthritis Rheum, volume 41, issue 1, pages 81-91, Jan 1998, doi <81::AID-ART11>3.0.CO;2-9 10.1002/1529-0131(199801)41:1<81::AID-ART11>3.0.CO;2-9, PMID 9433873
- ↑ L. Knott, N.C. Avery, A.P. Hollander, J.F. Tarlton, Regulation of osteoarthritis by omega-3 (n-3) polyunsaturated fatty acids in a naturally occurring model of disease, Osteoarthritis and Cartilage, volume 19, issue 9, 2011, pages 1150–1157, ISSN 10634584, doi 10.1016/j.joca.2011.06.005
- ↑ K.R. Baker, N.R. Matthan, A.H. Lichtenstein, J. Niu, A. Guermazi, F. Roemer, A. Grainger, M.C. Nevitt, M. Clancy, C.E. Lewis, J.C. Torner, D.T. Felson, Association of plasma n-6 and n-3 polyunsaturated fatty acids with synovitis in the knee: the MOST study, Osteoarthritis and Cartilage, volume 20, issue 5, 2012, pages 382–387, ISSN 10634584, doi 10.1016/j.joca.2012.01.021
- ↑ TE. McAlindon, P. Jacques, Y. Zhang, MT. Hannan, P. Aliabadi, B. Weissman, D. Rush, D. Levy, DT. Felson, Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis?, Arthritis Rheum, volume 39, issue 4, pages 648-56, Apr 1996, PMID 8630116
- ↑ NH. Jensen, [Reduced pain from osteoarthritis in hip joint or knee joint during treatment with calcium ascorbate. A randomized, placebo-controlled cross-over trial in general practice]., Ugeskr Laeger, volume 165, issue 25, pages 2563-6, Jun 2003, PMID 12854267
- ↑ I. Machtey, L. Ouaknine, Tocopherol in Osteoarthritis: a controlled pilot study., J Am Geriatr Soc, volume 26, issue 7, pages 328-30, Jul 1978, PMID 350940
- ↑ G. Blankenhorn, Clinical effectiveness of Spondyvit (vitamin E) in activated arthroses. A multicenter placebo-controlled double-blind study., Z Orthop Ihre Grenzgeb, volume 124, issue 3, pages 340-3, doi 10.1055/s-2008-1044572, PMID 3529677
- ↑ O. Scherak, G. Kolarz, C. Schödl, G. Blankenhorn, High dosage vitamin E therapy in patients with activated arthrosis., Z Rheumatol, volume 49, issue 6, pages 369-73, PMID 2085059
- ↑ C. Brand, J. Snaddon, M. Bailey, F. Cicuttini, Vitamin E is ineffective for symptomatic relief of knee osteoarthritis: a six month double blind, randomised, placebo controlled study., Ann Rheum Dis, volume 60, issue 10, pages 946-9, Oct 2001, PMID 11557651
- ↑ AE. Wluka, S. Stuckey, C. Brand, FM. Cicuttini, Supplementary vitamin E does not affect the loss of cartilage volume in knee osteoarthritis: a 2 year double blind randomized placebo controlled study., J Rheumatol, volume 29, issue 12, pages 2585-91, Dec 2002, PMID 12465157
- ↑ JJ. Gagnier, S. Chrubasik, E. Manheimer, Harpgophytum procumbens for osteoarthritis and low back pain: a systematic review., BMC Complement Altern Med, volume 4, pages 13, Sep 2004, doi 10.1186/1472-6882-4-13, PMID 15369596